Abstract
Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.
| Original language | English |
|---|---|
| Pages (from-to) | 183-185 |
| Number of pages | 3 |
| Journal | Japanese Journal of Clinical Oncology |
| Volume | 39 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2009 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adrenocortical carcinoma
- Chemotherapy
- Sunitinib
Fingerprint
Dive into the research topics of 'Metastatic adrenocortical carcinoma treated with sunitinib: A case report'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver